Literature DB >> 3874619

Aortic atherosclerosis in pigs with heterozygous von Willebrand disease. Comparison with homozygous von Willebrand and normal pigs.

L Badimon, P Steele, J J Badimon, E J Bowie, V Fuster.   

Abstract

We have reported that pigs with severe homozygous von Willebrand disease (vWd) are resistant to spontaneous and high fat, high cholesterol, diet-induced atherosclerosis. In this study we report the quantitation of aortic atherosclerotic plaques in three groups of pigs fed with a high fat, high cholesterol (2%) diet from age 3 to 9 months. Nine normal pigs (normal factor VIII antigen, VIII R:AG, and ristocetin co-factor, VIII:RWF) had a mean of 21% atherosclerotic involvement of the distal aortic surface and a 4.5% mean involvement of the entire aorta. Five homozygous vWd pigs (undetected VIII R:AG and VIII:RWF) had a mean of 4.2% atherosclerotic involvement of the distal aortic surface and 1.2% involvement of the entire aorta (p less than 0.01, rank sum test). Five heterozygous vWd pigs (approximately 35% VIII R:AG and VIII:RWF) had a mean of 25% atherosclerotic involvement of the distal aortic surface and 6% involvement of the entire aorta; the results were not significantly different from those in the normal pigs. We concluded that resistance to atherosclerosis is not found in animals with moderate reduction of VIII R:AG and VIII:RWF. This may have implications for humans, since in human vWd both factors are almost always present.

Entities:  

Mesh:

Year:  1985        PMID: 3874619     DOI: 10.1161/01.atv.5.4.366

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  8 in total

Review 1.  Arterial and venous thrombosis in patients with von Willebrand's disease: a critical review of the literature.

Authors:  A Girolami; F Tezza; M Scapin; S Vettore; A Casonato
Journal:  J Thromb Thrombolysis       Date:  2006-04       Impact factor: 2.300

Review 2.  How I treat patients with inherited bleeding disorders who need anticoagulant therapy.

Authors:  Karlyn Martin; Nigel S Key
Journal:  Blood       Date:  2016-04-22       Impact factor: 22.113

Review 3.  Hyperlipidaemia and cardioprotection: Animal models for translational studies.

Authors:  Ioanna Andreadou; Rainer Schulz; Lina Badimon; Adriana Adameová; Petra Kleinbongard; Sandrine Lecour; Panagiota-Efstathia Nikolaou; Ines Falcão-Pires; Gemma Vilahur; Nicholas Woudberg; Gerd Heusch; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2020-01-17       Impact factor: 8.739

4.  The Cardioprotective Potential of von Willebrand Disease in Ischemic Heart Disease.

Authors:  Nawfal Mihyawi; Muhammad Ajmal; Ayman R Fath; Bikash Bhattarai; Beeletsega Yeneneh
Journal:  Tex Heart Inst J       Date:  2022-07-01

5.  Porcine von Willebrand disease and atherosclerosis. Influence of polymorphism in apolipoprotein B100 genotype.

Authors:  T C Nichols; D A Bellinger; K E Davis; G G Koch; R L Reddick; M S Read; J Rapacz; J Hasler-Rapacz; K M Brinkhous; T R Griggs
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

Review 6.  Atherosclerosis and thrombosis: insights from large animal models.

Authors:  Gemma Vilahur; Teresa Padro; Lina Badimon
Journal:  J Biomed Biotechnol       Date:  2011-01-02

7.  Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies.

Authors:  Timothy C Nichols; Dwight A Bellinger; Elizabeth P Merricks; Robin A Raymer; Mark T Kloos; Natalie Defriess; Margaret V Ragni; Thomas R Griggs
Journal:  Thrombosis       Date:  2011-02-07

8.  The sequence and analysis of a Chinese pig genome.

Authors:  Xiaodong Fang; Yulian Mou; Zhiyong Huang; Yong Li; Lijuan Han; Yanfeng Zhang; Yue Feng; Yuanxin Chen; Xuanting Jiang; Wei Zhao; Xiaoqing Sun; Zhiqiang Xiong; Lan Yang; Huan Liu; Dingding Fan; Likai Mao; Lijie Ren; Chuxin Liu; Juan Wang; Kui Li; Guangbiao Wang; Shulin Yang; Liangxue Lai; Guojie Zhang; Yingrui Li; Jun Wang; Lars Bolund; Huanming Yang; Jian Wang; Shutang Feng; Songgang Li; Yutao Du
Journal:  Gigascience       Date:  2012-11-15       Impact factor: 6.524

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.